fig1
Figure 1. Potential therapeutic role of targeting microbial BSH expression in MASLD. MASLD: Metabolic dysfunction-associated steatotic liver disease; BSH: bile salt hydrolase; T-β-MCA: tauro-β-muricholic acid; FXR: farnesol X receptor; conBAs: conjugated bile acids; unconBAs: unconjugated bile acids; BAT: brown adipose tissue.
